Please login to the form below

Not currently logged in
Email:
Password:

Baxter to acquire Prism Pharma for $338m

Baxter International has entered into an agreement to acquire Prism Pharmaceuticals, a speciality pharma company based in King of Prussia, Pennsylvania

Baxter International has entered into an agreement to acquire Prism Pharmaceuticals, a speciality pharma company based in King of Prussia, Pennsylvania in a deal worth up to $338m. 

The terms of the agreement include an upfront payment of $170m with the potential for a further $168m in future milestone payments. 

Prism's product portfolio includes the anti-arrhythmic agent Nexterone (amiodarone HCl), which is approved by the US Food and Drug Administration (FDA) for multiple presentations including the first and only ready-to-use premixed intravenous (IV) bag formulations as well as vials and a pre-filled syringe.

"Nexterone is a great addition to our leading portfolio of premix drugs and solutions for the acute care setting. It offers clinicians a unique, ready-to-use anti-arrhythmic agent for critical and time sensitive situations, while also providing convenience to caregivers and value to pharmacists," said Robert M Davis, president of Baxter's Medical Products business. "Based on our strong hospital relationships and familiarity with the product, Baxter is well-positioned to launch the ready-to-use presentations of Nexterone."

The companies expect to close the deal during the second quarter of 2011.

19th April 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics